Response to: Human papillomavirus (HPV) vaccine safety concerning POTS, CRPS and related conditions
- 4 Downloads
Dear Editors,
We would like to thank Dr. Blitshteyn for her comments on the American Autonomic Society (AAS) statement on the relationship between human papillomavirus vaccine and autonomic disorder [1, 2]. Dr. Blitshteyn has highlighted that the case reports were not written to create an environment of fear and not meant to cause a reduction in vaccination rates. It was not the intent of the AAS statement to suggest that the case report authors were attempting to cause panic; however, the media reports on the complications associated with these small case reports have definitely resulted in a biased public perception of vaccinations. This has further resulted in an environment of fear, intentional or not, and caused a reduction in vaccination rates in many countries, and in some countries the HPV vaccine has been withdrawn [1, 3].
The Skufca Study in Finland did provide valuable information on the incidence of POTS in a general population pre-vaccine [4]. This was followed by a...
Notes
Funding
None.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interest.
References
- 1.Barboi A, Gibbons CH, Axelrod F et al (2019) Human papillomavirus (HPV) vaccine and autonomic disorders: a position statement from the American Autonomic Society. Clin Auton Res. https://doi.org/10.1007/s10286-019-00608-w CrossRefPubMedGoogle Scholar
- 2.Blitshteyn S (2020) Human papillomavirus (HPV) vaccines safety concerning POTS, CRPS and related conditions. Clin Auton Res. https://doi.org/10.1007/s10286-019-00653-5 CrossRefGoogle Scholar
- 3.Butts BN, Fischer PR, Mack KJ (2017) Human papillomavirus vaccine and postural orthostatic tachycardia syndrome: a review of current literature. J Child Neurol 32:956–965CrossRefGoogle Scholar
- 4.Skufca J, Ollgren J, Ruokokoski E, Lyytikainen O, Nohynek H (2017) Incidence rates of Guillain Barre (GBS), chronic fatigue/systemic exertion intolerance disease (CFS/SEID) and postural orthostatic tachycardia syndrome (POTS) prior to introduction of human papilloma virus (HPV) vaccination among adolescent girls in Finland, 2002–2012. Papillomavirus Res 3:91–96CrossRefGoogle Scholar
- 5.Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA (2018) The association of adverse events with bivalent human papilloma virus vaccination: a nationwide register-based cohort study in Finland. Vaccine 36:5926–5933CrossRefGoogle Scholar
- 6.Chandler RE, Juhlin K, Fransson J, Caster O, Edwards IR, Noren GN (2017) Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase((R)). Drug Saf 40:81–90CrossRefGoogle Scholar
- 7.European Medicines Agency (2015) Assessment report: review under Article 20 of Regulation (EC) No 726/2004. Human papillomavirus (HPV) vaccines. Pharmacovigilance Risk Assessment Committee (PRAC), EMA/762033/2015Google Scholar